Literature DB >> 2050072

Recent developments in the multistage modeling of cohort data for carcinogenic risk assessment.

S Mazumdar1, C K Redmond, J P Costantino, R N Patwardhan, S Y Zhou.   

Abstract

The modeling of cohort data based on the Armitage-Doll multistage model of the carcinogenic process has gained popular acceptance as a methodology for quantitative risk assessment for estimating the dose-related relationships between different occupational and environmental carcinogenic exposures and cancer mortality. The multistage model can be used for extrapolation to low doses relevant for setting environmental standards and also provides information regarding whether more than one stage is dose-related, which assists in determining whether different carcinogens affect different stages of the cancer process. This paper summarizes recent developments in the multistage modeling of cohort data and emphasizes practical issues such as handling data arising from large epidemiologic follow-up studies, the time-dependent nature of exposures and statistical issues such as multicollinearity in time-related variables, robustness of parameter estimates, validating of the fitted models, and routine inferential procedures. Problems related to uncertainties of risk estimates are discussed also. Computer programs for fitting multistage models with one or two dose-related stages to cohort data incorporating time-dependent exposure patterns; constructing confidence regions for model parameters; and predicting lifetime risks of dying from cancer adjusting for competing causes of death are detailed. Illustrations are provided using lung cancer mortality in a cohort of nonwhite male coke oven workers exposed to coal tar pitch volatiles.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2050072      PMCID: PMC1519516          DOI: 10.1289/ehp.90-1519516

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  8 in total

1.  Measuring the benefit of reduced exposure to environmental carcinogens.

Authors:  M Gail
Journal:  J Chronic Dis       Date:  1975-03

2.  Use of multistage models to infer stage affected by carcinogenic exposure: example of lung cancer and cigarette smoking.

Authors:  C C Brown; K C Chu
Journal:  J Chronic Dis       Date:  1987

Review 3.  Carcinogenesis modeling: from molecular biology to epidemiology.

Authors:  S H Moolgavkar
Journal:  Annu Rev Public Health       Date:  1986       Impact factor: 21.981

4.  Multistage model interpretation of additive and multiplicative carcinogenic effects.

Authors:  H J Gibb; C W Chen
Journal:  Risk Anal       Date:  1986-06       Impact factor: 4.000

5.  Multistage models and primary prevention of cancer.

Authors:  N E Day; C C Brown
Journal:  J Natl Cancer Inst       Date:  1980-04       Impact factor: 13.506

6.  A multistage approach to the cohort analysis of lifetime lung cancer risk among steelworkers exposed to coke oven emissions.

Authors:  M H Dong; C K Redmond; S Mazumdar; J P Costantino
Journal:  Am J Epidemiol       Date:  1988-10       Impact factor: 4.897

7.  Mutation and cancer: a model for human carcinogenesis.

Authors:  S H Moolgavkar; A G Knudson
Journal:  J Natl Cancer Inst       Date:  1981-06       Impact factor: 13.506

8.  A new method for the analysis of cohort studies: implications of the multistage theory of carcinogenesis applied to occupational arsenic exposure.

Authors:  C C Brown; K C Chu
Journal:  Environ Health Perspect       Date:  1983-04       Impact factor: 9.031

  8 in total
  3 in total

1.  Survey of methods and statistical models used in the analysis of occupational cohort studies.

Authors:  P W Callas; H Pastides; D W Hosmer
Journal:  Occup Environ Med       Date:  1994-10       Impact factor: 4.402

2.  Trends in quantitative cancer risk assessment.

Authors:  S C Morris
Journal:  Environ Health Perspect       Date:  1991-01       Impact factor: 9.031

3.  Reduced risk of all-cancer and solid cancer in Taiwanese patients with rheumatoid arthritis treated with etanercept, a TNF-α inhibitor.

Authors:  Joung-Liang Lan; Chun-Hung Tseng; Jiunn-Horng Chen; Chi-Fung Cheng; Wen-Miin Liang; Gregory J Tsay
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.